NASDAQ:CRON

Cronos Group (CRON) Stock Price, News & Analysis

Cronos Group logo
$3.17 -0.02 (-0.63%)
Closing price 04:00 PM Eastern
Extended Trading
$3.19 +0.02 (+0.63%)
As of 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About Cronos Group Stock (NASDAQ:CRON)

Advanced

Key Stats

Today's Range
$3.17
▼
$3.27
50-Day Range
$3.14
▼
$3.71
52-Week Range
$2.28
▼
$3.91
Volume
1.13 million shs
Average Volume
1.17 million shs
Market Capitalization
$1.16 billion
P/E Ratio
39.88
Dividend Yield
N/A
Price Target
$2.30
Consensus Rating
Buy

Company Overview

Cronos Group is a cannabinoid company that develops, produces, and markets cannabis and cannabis-derived products. Its business includes cultivation, processing, product development, and distribution.

The company sells products in categories such as dried cannabis flower, pre-rolls, vaporizers, edibles, and extracts. Its brand portfolio includes Spinach and PEACE NATURALS.

Founded in 2012 and headquartered in Toronto, Cronos serves consumers in Canada and select international markets, including Israel.

AI Generated. May Contain Errors.

Cronos Group Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
40th Percentile Overall Score

CRON MarketRank™: 
1.99214517876 of 5 stars

Cronos Group scored higher than 40% of companies evaluated by MarketBeat, and ranked 909th out of 1,706 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Cronos Group has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 strong buy rating, 3 buy ratings, 1 hold rating, and no sell ratings.

  • Downside Risk

    Cronos Group has a consensus price target of $2.30, representing about 27.4% downside from its current price of $3.17.

  • Amount of Analyst Coverage

    Cronos Group has only been the subject of 3 research reports in the past 90 days.

  • Read more about Cronos Group's stock forecast and price target.
  • Earnings Growth

    Earnings for Cronos Group are expected to grow by 62.50% in the coming year, from $0.16 to $0.26 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Cronos Group is 39.88, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 25.91.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Cronos Group is 39.88, which means that it is trading at a more expensive P/E ratio than the Healthcare sector average P/E ratio of about 33.58.

  • Price to Book Value per Share Ratio

    Cronos Group has a P/B Ratio of 1.03. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    1.23% of the float of Cronos Group has been sold short.
  • Short Interest Ratio / Days to Cover

    Cronos Group has a short interest ratio ("days to cover") of 4.94.
  • Change versus previous month

    Short interest in Cronos Group has recently increased by 4.87%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Cronos Group does not currently pay a dividend.

  • Dividend Growth

    Cronos Group does not have a long track record of dividend growth.

  • News Sentiment

    Cronos Group has a news sentiment score of 0.80. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.38 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 5 news articles for Cronos Group this week, compared to 4 articles on an average week.
  • Search Interest

    Only 4 people have searched for CRON on MarketBeat in the last 30 days. This is a decrease of -20% compared to the previous 30 days.
  • MarketBeat Follows

    5 people have added Cronos Group to their MarketBeat watchlist in the last 30 days. This is an increase of 67% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Cronos Group insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    7.80% of the stock of Cronos Group is held by insiders.

  • Percentage Held by Institutions

    8.71% of the stock of Cronos Group is held by institutions.

  • Read more about Cronos Group's insider trading history.
Receive CRON Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cronos Group and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

CRON Stock News Headlines

3 Canadian Penny Stocks To Own In November 2026
What the hell is going on?
Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and the shift is already underway. The dollar has lost 88% of its purchasing power since it was untethered from gold, and Fortune calls the current change the biggest shift in the world's relationship with the dollar in a generation. Stansberry says a similar reset is planned to be unveiled in Miami as soon as this December. Watch Porter Stansberry's full broadcast to see which companies could be affected.tc pixel
Top 3 Canadian Penny Stocks To Watch In November 2026
Canadian Penny Stocks To Watch In November 2026
Top 3 Canadian Penny Stocks To Watch In November 2026
See More Headlines

CRON Stock Analysis - Frequently Asked Questions

Cronos Group's stock was trading at $2.63 on January 1st, 2026. Since then, CRON stock has increased by 20.5% and is now trading at $3.17.

Cronos Group Inc. (NASDAQ:CRON) released its quarterly earnings results on Thursday, November, 5th. The company reported $0.04 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.03 by $0.01. The business earned $63.45 million during the quarter, compared to the consensus estimate of $51.15 million. Cronos Group had a trailing twelve-month return on equity of 2.56% and a net margin of 28.04%.
Read the conference call transcript
.

Top institutional investors of Cronos Group include Cibc World Market Inc. (0.35%), Silver Oak Securities Incorporated (0.19%), Goldman Sachs Group Inc. (0.18%) and HighTower Advisors LLC (0.10%).
View institutional ownership trends
.

Shares of CRON stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Cronos Group investors own include Canopy Growth (CGC), Aurora Cannabis (ACB), Tilray Brands (TLRY), NVIDIA (NVDA), Advanced Micro Devices (AMD), Micron Technology (MU) and Tesla (TSLA).

Company Calendar

Last Earnings
11/05/2026
Today
11/18/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceuticals
Sub-Industry
Pharmaceuticals
Current Symbol
NASDAQ:CRON
CIK
1656472
Fax
N/A
Employees
610
Year Founded
2013

Price Target and Rating

High Price Target
$2.30
Low Price Target
$2.30
Potential Upside/Downside
-27.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

EPS (Trailing Twelve Months)
$0.17
Trailing P/E Ratio
18.65
Forward P/E Ratio
12.19
P/E Growth
N/A
Net Income
-$9.45 million
Net Margins
28.04%
Pretax Margin
29.19%
Return on Equity
2.56%
Return on Assets
2.43%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
12.71
Quick Ratio
11.91

Sales & Book Value

Annual Sales
$206.20 million
Price / Sales
5.63
Cash Flow
$0.01 per share
Price / Cash Flow
260.83
Book Value
$3.07 per share
Price / Book
1.03

Miscellaneous

Outstanding Shares
366,471,000
Free Float
337,886,000
Market Cap
$1.16 billion
Optionable
Optionable
Beta
0.96

Social Links

Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven. Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

This page (NASDAQ:CRON) was last updated on 11/18/2026 by MarketBeat.com Staff.
From Our Partners